DGNOF (Diagnos) Treasury Stock : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Diagnos Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Diagnos's treasury stock for the quarter that ended in Sep. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Diagnos Treasury Stock Historical Data

The historical data trend for Diagnos's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diagnos Treasury Stock Chart

Diagnos Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Treasury Stock

Get a 7-Day Free Trial

Diagnos Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Diagnos Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Diagnos Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Diagnos Inc (OTCPK:DGNOF) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

ADK:Canada

Address

7005 Taschereau Boulevard, Suite 265, Brossard, Longueuil, QC, CAN, J4Z 1A7

Website

http://www.diagnos.ca

Diagnos Inc is engaged in the provision of software-based interpretation services to assist health specialists in the detection of diabetic retinopathy. The company provides image analysis services through CARA (Computer Assisted Retinal Analysis). It operates in the business segment of Healthcare services. The company has a business presence in Canada, the United States, Mexico, Chile, and others. The company's key revenue is derived from Canada.